Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.

Molecular imaging comprises a range of techniques, spanning not only several imaging modalities but also many disease states and organ sites. While advances in new technology platforms have enabled a deeper understanding of the cellular and molecular basis of malignancy, reliable non-invasive imaging metrics remain an important tool for both diagnostics and patient management. Furthermore, the non- invasive nature of molecular imaging can overcome shortcomings associated with traditional biological approaches and provide valuable information relevant to patient care. Integration of information from multiple imaging techniques has the potential to provide a more comprehensive understanding of specific tumor characteristics, tumor status, and treatment response.

[1]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[2]  David A. Mankoff,et al.  Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol , 2008, Journal of Nuclear Medicine.

[3]  G. Tortora,et al.  Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines , 2001, International journal of cancer.

[4]  P. Choyke,et al.  The biologic basis of in vivo angiogenesis imaging. , 2007, Frontiers in bioscience : a journal and virtual library.

[5]  B. Curry,et al.  ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. , 2000, Cancer research.

[6]  Andrea Sbarbati,et al.  Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma , 2005, Clinical Cancer Research.

[7]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[8]  Michael E. Phelps,et al.  Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors , 2006, Clinical Cancer Research.

[9]  Bradford A Moffat,et al.  Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker , 2004, Clinical Cancer Research.

[10]  D. Mankoff,et al.  Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Buck,et al.  Fluoro-3-Deoxythymidine ( [ 18 F ]-FLT ) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease , 2003 .

[12]  M. Fukui,et al.  Prolonged injection angiography for diagnosing intracranial cavernous hemangiomas. , 1979, Radiology.

[13]  Bradford A Moffat,et al.  An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. , 2007, Cancer research.

[14]  Jean Logan,et al.  Dopamine increases in striatum do not elicit craving in cocaine abusers unless they are coupled with cocaine cues , 2008, NeuroImage.

[15]  S H Kaufmann,et al.  Mammalian caspases: structure, activation, substrates, and functions during apoptosis. , 1999, Annual review of biochemistry.

[16]  M E Moseley,et al.  Comparison of diffusion‐ and T2‐weighted MRI for the early detection of cerebral ischemia and reperfusion in rats , 1991, Magnetic resonance in medicine.

[17]  M. Daemen,et al.  Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. , 2004, The New England journal of medicine.

[18]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[19]  Jae Seung Kim,et al.  [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Y. Yonekura,et al.  Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. , 2002, Nuclear medicine and biology.

[21]  T. Seierstad,et al.  Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  K W Ferrara,et al.  Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. , 2000, Academic radiology.

[23]  A. Kelekar Introduction to the review series Autophagy in Higher Eukaryotes--a matter of survival or death. , 2008, Autophagy.

[24]  A. Schroit,et al.  Aminophospholipid asymmetry: A matter of life and death. , 2003, Annual review of physiology.

[25]  D. Gospodarowicz,et al.  Characterization of the receptors for vascular endothelial growth factor. , 1990, The Journal of biological chemistry.

[26]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[27]  M. Muzi,et al.  Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. , 2004, Nuclear medicine and biology.

[28]  J. Little,et al.  Regulation by ionizing radiation of CDC2, cyclin A, cyclin B, thymidine kinase, topoisomerase IIalpha, and RAD51 expression in normal human diploid fibroblasts is dependent on p53/p21Waf1. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[29]  K. Linton,et al.  Membrane phosphatidylserine distribution as a non-apoptotic signalling mechanism in lymphocytes , 2005, Nature Cell Biology.

[30]  Thomas E Yankeelov,et al.  Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. , 2007, Magnetic resonance imaging.

[31]  W. Mikulits,et al.  Overexpression of Thymidine Kinase mRNA Eliminates Cell Cycle Regulation of Thymidine Kinase Enzyme Activity (*) , 1996, The Journal of Biological Chemistry.

[32]  John C Gore,et al.  Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer , 2008, Clinical Cancer Research.

[33]  B. Christian,et al.  Brain imaging of 18F‐fallypride in normal volunteers: Blood analysis, distribution, test‐retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D‐2/D‐3 receptors , 2002, Synapse.

[34]  Qiang Wang,et al.  ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.

[35]  K. Krohn,et al.  Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3'-deoxy-3'fluorothymidine uptake. , 2004, Nuclear medicine and biology.

[36]  A. Kimchi,et al.  Autophagy and tumor suppression: recent advances in understanding the link between autophagic cell death pathways and tumor development. , 2008, Advances in experimental medicine and biology.

[37]  Guido Kroemer,et al.  Cell death by mitotic catastrophe: a molecular definition , 2004, Oncogene.

[38]  D. Haber,et al.  Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. , 2007, Cancer research.

[39]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[40]  F. Blankenberg,et al.  In Vivo Detection of Apoptosis , 2008, Journal of Nuclear Medicine.

[41]  John C. Gore,et al.  A Molecular Imaging Paradigm to Rapidly Profile Response to Angiogenesis-directed Therapy in Small Animals , 2009, Molecular Imaging and Biology.

[42]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  L. Shen,et al.  Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. , 2008, Radiology.

[44]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[45]  James H Thrall,et al.  Imaging angiogenesis: applications and potential for drug development. , 2005, Journal of the National Cancer Institute.

[46]  C. Woffendin,et al.  Permeation and salvage of dideoxyadenosine in mammalian cells. , 1989, Molecular pharmacology.

[47]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[48]  R. Coffey,et al.  Characterization of the DiFi Rectal carcinoma cell line derived from a familial adenomatous polyposis patient , 1993, In Vitro Cellular & Developmental Biology - Animal.

[49]  Michael E Phelps,et al.  Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  C. Van de Wiele,et al.  99mTc-HYNIC Annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy. , 2007, The Quarterly Journal of Nuclear Medicine and Molecular Imaging.

[51]  Stefanie Mandl,et al.  Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  C. Van de Wiele,et al.  Intraobserver, interobserver, and day-to-day reproducibility of quantitative 99mTc-HYNIC annexin-V imaging in head and neck carcinoma. , 2004, Cancer biotherapy & radiopharmaceuticals.

[53]  J. P. Kennedy,et al.  Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells , 2009, Clinical Cancer Research.

[54]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[55]  H. Crijns,et al.  Noninvasive Detection of Programmed Cell Loss with 99mTc-Labeled Annexin A5 in Heart Failure , 2007, Journal of Nuclear Medicine.

[56]  Elias S. J. Arnér,et al.  Mammalian deoxyribonucleoside kinases. , 1995, Pharmacology & therapeutics.

[57]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[58]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[59]  P. Tofts Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[60]  Orhan Nalcioglu,et al.  Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer , 2003, Journal of magnetic resonance imaging : JMRI.

[61]  B. Munch‐Petersen,et al.  Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzymatic properties. , 1993, The Journal of biological chemistry.

[62]  Ping Zhao,et al.  Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer , 2009, Clinical Cancer Research.

[63]  J. Kucharczyk,et al.  Early detection of regional cerebral ischemia in cats: Comparison of diffusion‐ and T2‐weighted MRI and spectroscopy , 1990, Magnetic resonance in medicine.

[64]  D. Mankoff,et al.  Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  W. Schima,et al.  Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[66]  F. Blankenberg Molecular imaging: The latest generation of contrast agents and tissue characterization techniques , 2003, Journal of cellular biochemistry.

[67]  F. Blankenberg,et al.  99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[68]  S. Stone-Elander,et al.  Stereoselective binding of 11C-raclopride in living human brain — a search for extrastriatal central D2-dopamine receptors by PET , 2004, Psychopharmacology.

[69]  N. Rosen,et al.  Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. , 1995, The Journal of clinical investigation.

[70]  R. Wohlhueter,et al.  Nucleoside and nucleobase transport in animal cells. , 1988, Biochimica et biophysica acta.

[71]  R. Mach,et al.  Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. , 2006, Bioorganic & medicinal chemistry letters.

[72]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[73]  G. Tortora,et al.  Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy , 2004, Clinical Cancer Research.

[74]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[75]  R Iwata,et al.  Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[76]  J. Foidart,et al.  In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. , 2005, Nuclear medicine and biology.

[77]  G. Martiny-Baron,et al.  Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. , 2000, Cancer research.

[78]  D. Dean,et al.  Transcriptional Repression by Rb-E2F and Regulation of Anchorage-Independent Survival , 2001, Molecular and Cellular Biology.

[79]  P. Thimister,et al.  In vivo detection of cell death in the area at risk in acute myocardial infarction. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[80]  I. Baumann,et al.  Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal--implications for antiphospholipid syndrome and systemic lupus erythematosus. , 2003, Immunobiology.

[81]  D. Chang,et al.  Dynamics and structure of the Bax-Bak complex responsible for releasing mitochondrial proteins during apoptosis , 2008, Journal of Cell Science.

[82]  M. Droller Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 2000, The Journal of urology.

[83]  H. Dittmann,et al.  [18F]FLT PET for diagnosis and staging of thoracic tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[84]  F. Blankenberg,et al.  Annexin V SPECT imaging of phosphatidylserine expression in patients with dementia , 2006, Neurology.

[85]  William E Grizzle,et al.  Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. , 2008, Radiology.

[86]  M. Hengartner The biochemistry of apoptosis , 2000, Nature.

[87]  William R. Wagner,et al.  Targeted In Vivo Labeling of Receptors for Vascular Endothelial Growth Factor , 2003, Circulation.

[88]  G. Slegers,et al.  Prognostic value of 99mTc-HYNIC Annexin-V imaging in squamous cell carcinoma of the head and neck , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[89]  Christopher Nimsky,et al.  Metabolic Imaging of Cerebral Gliomas: Spatial Correlation of Changes in O-(2-18F-Fluoroethyl)-l-Tyrosine PET and Proton Magnetic Resonance Spectroscopic Imaging , 2008, Journal of Nuclear Medicine.

[90]  Roy Bicknell,et al.  The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. , 2002, Cancer research.

[91]  G. Antoni,et al.  Molecular Imaging of Neurovascular Cell Death in Experimental Cerebral Stroke by PET , 2008, Journal of Nuclear Medicine.

[92]  J. Galons,et al.  MRI‐measured water mobility increases in response to chemotherapy via multiple cell‐death mechanisms , 2007, NMR in biomedicine.

[93]  R. Weissleder,et al.  Optimal Modification of Annexin V with Fluorescent Dyes , 2004, Chembiochem : a European journal of chemical biology.

[94]  T K Lewellen,et al.  Carbon-11-thymidine and FDG to measure therapy response. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[95]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[96]  Marvin Bergsneider,et al.  Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[97]  F. Hoebers,et al.  In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[98]  J. Frangioni,et al.  Intraoperative Detection of Cell Injury and Cell Death with an 800 nm Near‐Infrared Fluorescent Annexin V Derivative , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[99]  Vimalkumar A. Patel,et al.  In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[100]  R. Nishii,et al.  Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model. , 2006, Nuclear medicine and biology.

[101]  Paul Workman,et al.  In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. , 2006, Cancer research.

[102]  G. Gallick,et al.  Treatment for Advanced Tumors: Src Reclaims Center Stage , 2006, Clinical Cancer Research.

[103]  M. Day,et al.  pRb-Independent growth arrest and transcriptional regulation of E2F target genes. , 2005, Neoplasia.

[104]  M. Watson,et al.  Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines , 2008, Journal of Nuclear Medicine.

[105]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[106]  Sanjiv S Gambhir,et al.  PET of vascular endothelial growth factor receptor expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[107]  A. Guha,et al.  A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[108]  Qimin He,et al.  3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.

[109]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[110]  J. Medema,et al.  Apoptosis and non-apoptotic deaths in cancer development and treatment response. , 2008, Cancer treatment reviews.

[111]  Jan Wolber,et al.  Diffusion MRI for prediction of response of rectal cancer to chemoradiation , 2002, The Lancet.

[112]  Bradford A Moffat,et al.  Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[113]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[114]  J. Mendelsohn,et al.  Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. , 1984, The Journal of biological chemistry.

[115]  D. Hicklin,et al.  Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[116]  W. Oyen,et al.  Annexin A5 Scintigraphy of Forearm as a Novel In Vivo Model of Skeletal Muscle Preconditioning in Humans , 2005, Circulation.

[117]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[118]  Adam P Dicker,et al.  Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: preliminary results. , 2002, Ultrasound in medicine & biology.

[119]  V. Ntziachristos,et al.  Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[120]  Thomas E Yankeelov,et al.  New insights into tumor microstructure using temporal diffusion spectroscopy. , 2008, Cancer research.

[121]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[122]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[123]  D. Collins,et al.  Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. , 2007, AJR. American journal of roentgenology.

[124]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[125]  F. Blankenberg,et al.  In vivo imaging of apoptosis in patients with acute stroke: Correlation with blood–brain barrier permeability , 2006, Brain Research.

[126]  Y. Yarden,et al.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.

[127]  A. Schroit,et al.  Regulated Externalization of Phosphatidylserine at the Cell Surface , 2007, Journal of Biological Chemistry.

[128]  H. Bartelink,et al.  In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. , 2004, International journal of radiation oncology, biology, physics.

[129]  Marina V Backer,et al.  Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes , 2007, Nature Medicine.